» Articles » PMID: 12606508

Nocturnal and Postprandial Free Fatty Acid Kinetics in Normal and Type 2 Diabetic Subjects: Effects of Insulin Sensitization Therapy

Overview
Journal Diabetes
Specialty Endocrinology
Date 2003 Feb 28
PMID 12606508
Citations 51
Authors
Affiliations
Soon will be listed here.
Abstract

Whether free fatty acid (FFA) rate of appearance (R(a)) is increased in type 2 diabetes is controversial. To characterize nocturnal and postprandial abnormalities in FFA kinetics and to determine the effects of treatment with insulin sensitizers on lipolysis, we measured palmitate R(a) in control subjects (n = 6) and individuals with poorly controlled, sulfonylurea-treated type 2 diabetes (HbA(1c) = 8.7 +/- 0.2%, n = 20), the latter before and at the end of 12 weeks of treatment with troglitazone (600 mg/day, n = 4), metformin ( approximately 2,000 mg/day, n = 8), or placebo (n = 8). Subjects consumed a standard breakfast at 0800 h. Results in control subjects and type 2 diabetic subjects were compared at baseline. Integrated nocturnal FFA R(a) (AUC(1:00-8:00 A.M.)) was approximately 50% higher in type 2 diabetic subjects than in control subjects (29.4 +/- 3.0 vs. 19.4 +/- 3.9 mmol. m(-2). 7 h(-1), respectively, P < 0.05), whereas postprandial palmitate R(a) (AUC(0-240 min)) was almost threefold higher in type 2 diabetic subjects than in control subjects (14.2 +/- 1.7 vs. 5.3 +/- 1.0 mmol. m(-2). 4 h(-1), respectively, P < 0.01). After troglitazone treatment, nocturnal palmitate R(a) did not change, but postprandial palmitate R(a) decreased by approximately 30% (P < 0.05). Palmitate kinetics did not change with metformin or placebo treatment. In summary, nocturnal and postprandial FFA R(a) is increased in type 2 diabetes. Postprandial lipolysis appears to be preferentially improved by thiazolidinediones compared with nocturnal lipolysis.

Citing Articles

An adipocentric perspective of pancreatic lipotoxicity in diabetes pathogenesis.

Risi R, Vidal-Puig A, Bidault G J Endocrinol. 2024; 262(1).

PMID: 38642584 PMC: 11227041. DOI: 10.1530/JOE-23-0313.


Obesity, diabetes mellitus, and cardiometabolic risk: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2023.

Bays H, Bindlish S, Clayton T Obes Pillars. 2023; 5:100056.

PMID: 37990743 PMC: 10661981. DOI: 10.1016/j.obpill.2023.100056.


Role of prior feeding status in mediating the effects of exercise on blood glucose kinetics.

Moreno-Cabanas A, Gonzalez J Am J Physiol Cell Physiol. 2023; 325(4):C823-C832.

PMID: 37642241 PMC: 10635662. DOI: 10.1152/ajpcell.00271.2023.


The Impacts of Animal-Based Diets in Cardiovascular Disease Development: A Cellular and Physiological Overview.

Najjar R J Cardiovasc Dev Dis. 2023; 10(7).

PMID: 37504538 PMC: 10380617. DOI: 10.3390/jcdd10070282.


Serum Fibroblast Growth Factor 21 Level After an Oral Fat Tolerance Test is Related to Postprandial Free Fatty Acid Level.

Li X, Zheng K, Gu W, Hou X, Guan Y, Liu L Diabetes Metab Syndr Obes. 2023; 16:1567-1576.

PMID: 37283621 PMC: 10241254. DOI: 10.2147/DMSO.S410457.